CD274 and renal cell carcinoma: Randomized Phase III studies have also shown that treatment with antiangiogenic agents in combination with programmed cell death ligand 1 (PD-L1) antibodies significantly improves survival compared with standard therapy in renal cell carcinoma (RCC), NSCLC and hepatocellular carcinoma (HCC) (Hack et al. 2020).